FOR RELEASE: August 24, 1993
REVLON, INC. TO SETTLE CHARGES OF UNSUBSTANTIATED AD CLAIMS FOR "ANTI-CELLULITE" AND SUNSCREEN PRODUCTS
Revlon, Inc. and its subsidiary, Charles Revson, Inc., have agreed to settle Federal Trade Commission charges of unsubstan- tiated advertising claims for their Ultima II ProCollagen Anti- cellulite body complex ("Anti-cellulite body complex") and PhotoAging Shield ("PAS") products. A proposed consent agreement would require competent and reliable scientific evidence to substantiate such claims in the future.
Revlon, Inc. is a Delaware corporation and Charles Revson, Inc. is a New York corporation, both with headquarters in New York City.
According to the complaint attached to the agreement, through statements and depictions in advertising and promotional materials, Revlon claimed that its ProCollagen body complex:
-- significantly reduces cellulite;
-- reduces skin's bumpy texture, ripples or slackness caused by cellulite;
-- helps disperse toxins and excess water from areas where cellulite appears; and
-- increases sub-skin tissue strength and tone.
The complaint charges Revlon with representing that it had a reasonable basis for such claims when, in fact, it did not.
In addition, according to the FTC, Revlon marketed PAS as a product intended to prevent "photoaging." Photoaging occurs when the ultraviolet rays (UV) from natural sunlight, and possibly
- more - (Revlon--08/24/93)
from artificial light, cause the skin to become prematurely wrinkled and leathery. According to the Commission's complaint, Revlon advertising and promotional materials for PAS contained the following claims:
-- "While you can't prevent biological aging, you can prevent Photoaging...This revolutionary product acts as a shield for your skin;" and
-- "It's called PhotoAging Shield and it's so protective it actually intercepts damaging light waves before they penetrate your skin."
The FTC alleged that these and other statements and depictions in advertisements and promotional materials have represented that PAS blocks all of the harmful rays which cause photoaging. The complaint alleges that Revlon falsely represented that it had a reasonable basis for such a claim.
The proposed consent agreement to settle these charges, announced today for public comment, would require Revlon to have scientific evidence to support any future claims about the effectiveness of cellulite treatments or sunscreen products. Revlon also would be required to disclose the sun protection factor (SPF) value in any sunscreen ad in which it touts the ability of the product to protect against the sun's rays.
The order also would permit representations for sunscreen products that the Food and Drug Administration (FDA) establishes as supported by scientific evidence in a tentative final or final standard. FDA issued a tentative final monograph on over-the- counter sunscreen drug products on May 12, 1993.
The Commission vote to amend the complaint and accept the proposed consent agreement for public comment was 5-0.
A fact sheet on sunscreen products and the type of protection they offer is available from the FTC.
The proposed consent agreement will be published in the Federal Register shortly. It will be subject to public comment for 60 days, after which the Commission will decide whether to make it final. Comments should be addressed to: Office of the Secretary, Federal Trade Commission, 6th Street and Pennsylvania Avenue, N.W., Washington, D.C. 20580.
NOTE: A consent agreement is for settlement purposes only and does not constitute an admission of a law violation. When the Commission issues a consent order on a final basis, it carries
the force of law with respect to future actions. Each violation of such an order may result in a civil penalty of up to $10,000.
Copies of the amended complaint, (entitled "Amended Com- plaint" because it supersedes a previously approved administra- tive complaint concerning only the cellulite product) the consent agreement, an analysis of the agreement to aid the public in commenting, and the consumer fact sheet, Sunscreens, are available from the FTC's Public Reference Branch, Room 130, at the above address.
# # #
MEDIA CONTACT: Howard Shapiro, Office of Public Affairs 202-326-2176
STAFF CONTACT: Phoebe D. Morse, Boston Regional Office 10 Causeway Street, Room 1184 Boston, Massachusetts 02222 617-565-7240 or Brinley H. Williams, Cleveland Regional Office 668 Euclid Avenue, Suite 520-A Cleveland, Ohio 44114 216-522-4207
(FTC Docket No. 9231)
(FTC File No. 882 3110)